September Pharmaceutical Event Policy Article: New changes in the industry are on the way

In September, new pharmaceutical policies and regulations were issued frequently, mainly related to Internet medical care, medical insurance, pharmaceutical prices and recruitment, medical personnel, medical education and other aspects, will bring new changes to various sub-sectors.
"The new industry model to lead the new mode of consumption to accelerate the development of the opinion" released, good Internet medical recently, China released the "new industry model to lead the new mode of consumption to accelerate the development of the opinion" clearly, will actively carry out artificial intelligence applications in the field of consumer services, enrich 5G technology applications, accelerate the development of wearable devices, medical electronics, medical robots and other intelligent products, enhance the support of new consumer technology.
, it also explicitly mentioned the need to actively develop Internet health care services, and vigorously promote time-by-time appointments, Internet consultations, electronic prescription transfer, drug network sales and other services.
industry believes that this also means that the Internet healthcare industry once again ushered in a policy of good.
three departments issued "guidance on strengthening and improving basic medical insurance coverage" a few days ago, the State Health Insurance Administration and other three departments issued "guidance on strengthening and improving basic medical insurance coverage work."
It is clear that from the year of insurance coverage in 2021, the national insurance information will be interconnected, dynamically updated, can be queried in real time, the quality of insured information has improved significantly;
The main tasks assigned in accordance with the documents include setting reasonable targets for the expansion of insurance, implementing the policy of insurance contributions, bridging the treatment of cross-system insurance participation, orderly cleaning up of duplicate insurance, improving the mechanism of individual insurance contribution services, and strengthening the management of financial assistance funds.
September 16th, the State Health Insurance Administration officially published the Guidance on the Establishment of a Credit Evaluation System for Pharmaceutical Prices and Recruitment.
which clearly will adhere to the innovation of pharmaceutical price management, based on the drug and medical supplies centralized procurement of the contract relationship between the sale, relying on the pharmaceutical and medical supplies tender procurement platform, systematic integration of trustworthy commitments, credit rating, graded disposal, credit repair and other mechanisms, the establishment of equal rights and responsibilities, coordination of the linked pharmaceutical prices and credit evaluation system.
the system is considered by the industry to be the National Health Insurance Administration issued by the drug companies market access "blacklist" system.
A few days before the release of the Notice on Strengthening the Administration of Narcotic Drugs and One Class of Psychotic Drugs in Medical Institutions, the State Health and Health Commission issued a notice on strengthening the management of narcotic drugs and a class of psychotic drugs in medical institutions, which is based on the main problems existing in the management of hemp essence drugs in medical institutions and puts forward seven specific requirements.
Including health administrative departments and medical institutions at all levels should attach great importance to the management of hemp essence drugs, improve the management system of hemp essence drugs in medical institutions, strengthen the management of all aspects of the whole process of hemp essence drugs, standardize the prescription authority and operation management of hemp essence drugs, meet the needs of clinically reasonable hemp essence drugs, strengthen supervision and guidance and accountability.
with the release of the document, it will be conducive to strengthening the management of narcotic drugs and a class of psychotic drugs (hereinafter referred to as hemp essence drugs) in medical institutions, ensuring reasonable clinical needs and strictly preventing the flow of illegal channels.
"Guidance on accelerating the development of innovation in medical education" issued recently, the state issued "guidance on accelerating the development of innovation in medical education."
, which put forward the requirements for the credit certification of continuing medical education and the promotion of the innovation and development of continuing medical education.
Which clearly in accordance with the requirements, medical personnel continue to medical education will be included in the annual quarterly assessment, in terms of funding, employers need to increase investment, according to the law to extract and use staff education funds, in the evaluation of the title of health professional and technical personnel, should highlight the character, ability and performance-oriented, emphasizing clinical practice and other business ability, to break the paper-only tendency.
, the industry believes that in the continuing education of medical personnel and the evaluation of the title of the way of great changes, pharmaceutical companies with gold sales and other acts will lose the living space.
The Announcement on the Collection of Clues on the Collection of Comprehensive Supervision and Inspection of the Health Care Industry in 2020 disclosed recently that the General Supervision Bureau of the National Health and Welfare Commission issued a Notice on the Collection of Clues on the Collection of Comprehensive Supervision and Inspection of the Health care Industry in 2020, saying that the National Health and Safety Commission is scheduled to organize comprehensive supervision and supervision of the medical and health industry in late September, and conduct field inspections in 19 provinces (regions, cities) and Xinjiang Production and Construction Corps, including Beijing and Hebei.
inspection, which is aimed at the whole country, is a large-scale top-down overhaul that will involve all medical institutions and medical personnel.
, the industry believes that this round of nationwide medical clean-up efforts will be even more than before.
September 8th, the State Drug Administration issued the Notice on the Cancellation of 78 Drug Registration Certificates for Injection Use, etc. (No. 96 of 2020).
the relevant provisions, the State Drug Administration decided to cancel the injection of the forefront of the 78 drug registration certificates.
From the list, these 78 drugs are mostly commonly used drugs, including paediaminophen jaundol sensitive particles, injection of progestin, Malay acid chlorobenamide tablets, cephalosporine particles, amosillin capsules, isoniazid tablets, silver yellow particles, hydrochloric acid renitin capsules and other common varieties.
the relevant regulations, these drugs will not be available on the market.
the Interim Measures for the Administration of Drug Use in Basic Medical Insurance shall be implemented in accordance with the documents of the State Administration of Medical Insurance, and from September 1, 2020, the Interim Measures for the Administration of Drug Use for Basic Medical Insurance will come into effect.
note that the Basic Medical Insurance Drug Catalog, developed by the Scheme, states that eight categories of medicines may not be included in the catalogue.
Specifically: preventive vaccines; tonic drugs; health drugs; hair loss, beauty weight loss and other enhanced functional drugs; drugs that cannot be charged separately for reasons such as inclusion in medical treatment programs; medicines containing national precious and endangered wildlife herbs, etc.
not be included in the list, which also means that the eight types of medical insurance will not be reimbursed.